NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,654.7 mln
Float91.86 mln
Earnings Date08/12/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
59.00
Attractive
Relative Strength
46
/ 100
Slightly lagging
Debt / Equity
0.75
Moderate leverage
ROE
-156
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, focused on treating rare and serious muscle and nerve diseases, including spinal muscular atrophy. The company has built a drug discovery platform that targets specific proteins responsible for muscle loss and disease progression, which has produced several drug candidates at various stages of clinical testing. Its leading medicine, Apitegromab, is currently in clinical trials for spinal muscular atrophy, while other compounds are being studied for conditions such as solid tumors resistant to standard therapies, fibrotic diseases, and certain forms of anemia. Founded in 2012, Scholar Rock continues to expand its research pipeline with the goal of addressing conditions that currently have few or no effective treatment options.